

20th March 2018

- | | |
|---|---|
| (1) BSE Ltd
Listing Department,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001 | (2) National Stock Exchange of India Ltd
Listing Department,
Exchange Plaza, 5 th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051 |
|---|---|

Scrip Code: 500087

Scrip Code: CIPLA EQ

- (3) SOCIETE DE LA BOURSE DE LUXEMBOURG
Societe Anonyme
35A, Boulevard Joseph II
L-1840 Luxembourg


Dear Sirs,

This has reference to your email dated 20th March 2018 regarding news item appearing on www.moneycontrol.com titled "Cipla shares drop 7% on USFDA observations for Goa unit".

We wish to inform you that the US FDA conducted a product specific pre-approval inspection at our Goa plant in January 2018. We received certain observations which are procedural in nature. We have already responded to the agency on all the observations. At this stage, we do not foresee any impact on the other products being manufactured/filed from the plant. Post this inspection, we have received 2 product approvals from the plant.

Thank you,

Yours faithfully,
For Cipla Limited



Rajendra Chopra
Company Secretary